ClinicalTrials.gg
CompletedNCT00931918Updated Jan 11, 2017Results posted

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

A Phase 2 interventional study of Bortezomib and Rituximab in Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL), sponsored by Millennium Pharmaceuticals, Inc.. Completed at 70 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-11.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
206
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing bortezomib in Lymphoma, Large B-Cell, Diffuse — none open to participants now, none under way, none of them phase 3. Bortezomib · Lymphoma, Large B-Cell, Diffuse.

Enrollment
3rd of 26
206 · median 35
Started
2009
with 2 others
Phase 2
13 of 29
none open now
Registered
15th of 29
by date
Lead sponsor
2 of 29
Millennium Pharmaceuticals, Inc.

Among the 29 studies testing bortezomib in Lymphoma, Large B-Cell, Diffuse, this one is the 3rd largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2009, is one of 13 in phase 2, and was the 15th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

None of the 29 studies testing bortezomib in Lymphoma, Large B-Cell, Diffuse is open now. The open studies under Lymphoma, Large B-Cell, Diffuse, anywhere →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies testing bortezomib in Lymphoma, Large B-Cell, Diffuse as a file.
02

Study summary

This is a randomized, open-label, multi-center, phase 2 study of RCHOP with or without VELCADE in adult patients with previously untreated non-(Germinal B-Cell-like) GCB Diffuse Large B-cell Lymphoma (DLBCL). The study will determine whether the addition of VELCADE to RCHOP improves progression-free survival (PFS) in patients with non-GCB DLBCL.

Read the detailed description

The drug tested in this study is called bortezomib (VELCADE®). VELCADE® was tested in people who have Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma. This study looked at the efficacy of RCHOP [rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone] with or without VELCADE®.

The study enrolled 206 patients. Participants were enrolled in one of the two open label treatment groups:

  • RCHOP
  • Vc-RCHOP [bortezomib (VELCADE®), rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone]

Participants received treatment for up to six, 21-day cycles.

This multi-center trial was conducted in the United States. The overall time to participate in this study was up to 48 months. Participants made multiple visits to the clinic, and were followed for progression free survival and overall survival until patient withdrawal, death, or 2 years after the last participant was enrolled.

03

Conditions studied

  • Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Each patient must meet all of the following inclusion criteria to be enrolled in the study:

Inclusion criteria

Inclusion Criteria:

  • Patients with previously untreated DLBCL that has been sub classified as the non-GCB subtype.
  • At least 1 measurable tumor mass.
  • Availability of paraffin block with sufficient tumor tissue.
  • No evidence of central nervous system lymphoma.
  • (ECOG) performance status of \< or equal to 2.
  • Female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of or abstain from heterosexual intercourse.
  • Male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse.

Patients meeting any of the following exclusion criteria are not to be enrolled in the study:

Exclusion criteria

Exclusion Criteria:

  • Diagnosed or treated for a other than DLBCL within 2 years of first dose or evidence of active malignancy other than DLBCL.
  • Peripheral neuropathy of Grade 2 or greater.
  • Known history of (HIV) infection, unless receiving highly active antiretroviral therapy (HAART).
  • Active infection requiring systemic therapy.
  • Major surgery within 2 weeks before first dose.
  • Patients with a (LVEF) or less than 45%.
  • Myocardial infarction with 6 months of enrollment or evidence of current uncontrolled cardiovascular conditions as described in the protocol.
  • History of allergic reaction/ attributable to boron, mannitol, polysorbate 80 or sodium citrate dehydrate, or anaphylaxis or immunoglobulin E (IgE)-mediated hypersensitivity to murine proteins or to any component of rituximab.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
206 participants (actual)

Study arms

  • Active comparator
    RCHOP

    RCHOP \[rituximab, cyclophosphamide, doxorubicin, prednisone\] administered as follows: rituximab 375 mg/m\^2 intravenous (IV) infusion, cyclophosphamide 750 mg/m\^2 IV infusion, doxorubicin 50 mg/m\^2 IV injection and vincristine 1.4 mg/m\^2 (maximum total dose 2 mg) IV injection on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.

    Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone

  • Experimental
    Vc-RCHOP

    Vc-RCHOP \[bortezomib (VELCADE®), rituximab, cyclophosphamide, doxorubicin, prednisone\] administered as follows: bortezomib (VELCADE ®) 1.3 mg/m\^2 administered intravenous (IV) push on Days 1 and 4 of each cycle with RCHOP administered as follows: rituximab 375 mg/m\^2 intravenous (IV) infusion, cyclophosphamide 750 mg/m\^2 IV infusion, doxorubicin 50 mg/m\^2 IV injection and vincristine 1.4 mg/m\^2 (maximum total dose 2 mg) IV injection on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.

    Drug: Bortezomib · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) in Patients With Non-germinal Center B-cell-like (Non-GCB) Diffuse Large B-cell Lymphoma (DLBCL)

    PFS is defined as the time in months from the date of randomization to the date of first documentation of progressive disease (PD) or death from any cause. The date of progression is the earliest date of a computed tomography/positron emission tomography (CT/PET) scan that shows evidence of PD. For a participant that has not progressed and is alive at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), PFS is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. PD= any new lesion or increase by \> 50% of previously involved sites from nadir.

    Time frame: Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm

  2. Progression-Free Survival Rate

    PFS is defined as the time in months from the date of randomization to the date of first documentation of progressive disease (PD) or death from any cause. The date of progression is the earliest date of a computed tomography/positron emission tomography (CT/PET) scan that shows evidence of PD. For a participant that has not progressed and is alive at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), PFS is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. PD= any new lesion or increase by \> 50% of previously involved sites from nadir. The progression-free survival rate is defined as the Kaplan-Meier (KM) estimate of progression-free survival at 2 years.

    Time frame: 2 Years (Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm)

Secondary outcomes

  1. Overall Survival

    Overall survival is defined as the time from the date of randomization to the date of death from any cause. A participant who is alive at the end of his/her study follow-up is censored at the date of last contact.

    Time frame: Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm

  2. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants with the best overall response complete response (CR) + partial response (PR). Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. CR=disappearance of all evidence of disease and PR=regression of measurable disease and no new sites.

    Time frame: End of Cycle 2, End of Treatment (Cycle 6) [Median of 16 weeks on treatment]

  3. Complete Response Rate

    Complete Response Rate is defined as the percentage of participants with the best response of Complete Response (CR). Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. CR=Disappearance of all evidence of disease.

    Time frame: End of Cycle 2, End of Treatment (Cycle 6) [Median of 16 weeks on treatment]

  4. Duration of Response

    Duration of response is defined as the time (in months) from the date of first documentation of confirmed complete response (CR) or partial response (PR) to the date of first documentation of progressive disease (PD), relapse from CR or death related to disease. For a participant who has not progressed and is not known to have died due to disease under study at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), duration of response is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using IWG-revised response criteria for malignant lymphoma. CR=Disappearance of all evidence of disease and PR=Regression of measurable disease and no new sites and PD= any new lesion or increase by \> 50% of previously involved sites from nadir.

    Time frame: Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm

  5. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Negative Rate

    FDG-PET negative rate is defined as the percentage of participants FDG-PET negative at the given time-point.

    Time frame: End of Cycle 2 and End of Treatment (Cycle 6) [Median of 16 weeks on treatment]

  6. Time to Progression (TTP)

    TTP is defined as the time from the date of randomization to the date of first documentation of progressive disease, relapse from CR, or death related to disease under study if participant did not have any documentation of disease progression prior to death caused by lymphoma or complications thereof. For a participant who has not progressed and is not known to have died due to disease under study at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), TTP is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. PD= any new lesion or increase by \> 50% of previously involved sites from nadir.

    Time frame: Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm

  7. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) by Category

    Percentage of participants in the following categories: • At least 1 TEAE • Drug-related, TEAEs • Grade 3 or higher TEAEs. Grade 3 are AEs of Severe Intensity • Grade 3 or higher drug-related, TEAEs • TEAEs resulting in study drug discontinuation • Serious TEAEs An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A Serious Adverse Event (SAE) is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: First dose of study drug through 30 days after the last dose of study drug (Up to 26 Weeks)

  8. Percentage of Participants With Chemistry and Hematology Laboratory Values Grade 3 or Higher

    Percentage of participants who shifted from a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 0, 1, or 2 at Baseline to a Grade 3 or higher on study (worst post-baseline grade). Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe or medically significant but not immediately life-threatening, Grade 4=Life-threatening consequences and 5=Death related to AE.

    Time frame: Days 1, 4 and 10 of each cycle and end of treatment visit (Median of 16 weeks on treatment)

07

Results

Posted Jan 11, 2017

Participant flow

Participants took part in the study at 69 investigative sites in the United States from 13 October 2009 to 15 August 2015.

Participant flow — Overall Study
MilestoneRCHOPVc-RCHOP
Started103103
Safety population: received study drug100101
Completed8686
Not completed1717
Withdrew: Adverse event46
Withdrew: Progressive disease21
Withdrew: Symptomatic deterioration10
Withdrew: Withdrawal by patient34
Withdrew: Other reason not specified44
Withdrew: Did not receive study drug32

Outcome measures

PrimaryProgression-Free Survival (PFS) in Patients With Non-germinal Center B-cell-like (Non-GCB) Diffuse Large B-cell Lymphoma (DLBCL)

PFS is defined as the time in months from the date of randomization to the date of first documentation of progressive disease (PD) or death from any cause. The date of progression is the earliest date of a computed tomography/positron emission tomography (CT/PET) scan that shows evidence of PD. For a participant that has not progressed and is alive at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), PFS is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. PD= any new lesion or increase by \> 50% of previously involved sites from nadir.

Time frame:
Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm
Reported as:
Median · months
Progression-Free Survival (PFS) in Patients With Non-germinal Center B-cell-like (Non-GCB) Diffuse Large B-cell Lymphoma (DLBCL)
monthsRCHOPVc-RCHOP
Progression-Free Survival (PFS) in Patients With Non-germinal Center B-cell-like (Non-GCB) Diffuse Large B-cell Lymphoma (DLBCL)NA (NA to NA)NA (NA to NA)
PrimaryProgression-Free Survival Rate

PFS is defined as the time in months from the date of randomization to the date of first documentation of progressive disease (PD) or death from any cause. The date of progression is the earliest date of a computed tomography/positron emission tomography (CT/PET) scan that shows evidence of PD. For a participant that has not progressed and is alive at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), PFS is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. PD= any new lesion or increase by \> 50% of previously involved sites from nadir. The progression-free survival rate is defined as the Kaplan-Meier (KM) estimate of progression-free survival at 2 years.

Time frame:
2 Years (Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm)
Reported as:
Number · percentage of participants
Progression-Free Survival Rate
percentage of participantsRCHOPVc-RCHOP
Progression-Free Survival Rate7882
SecondaryOverall Survival

Overall survival is defined as the time from the date of randomization to the date of death from any cause. A participant who is alive at the end of his/her study follow-up is censored at the date of last contact.

Time frame:
Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm
Reported as:
Median · months
Overall Survival
monthsRCHOPVc-RCHOP
Overall SurvivalNA (NA to NA)NA (NA to NA)
SecondaryOverall Response Rate (ORR)

ORR is defined as the percentage of participants with the best overall response complete response (CR) + partial response (PR). Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. CR=disappearance of all evidence of disease and PR=regression of measurable disease and no new sites.

Time frame:
End of Cycle 2, End of Treatment (Cycle 6) [Median of 16 weeks on treatment]
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsRCHOPVc-RCHOP
End of Cycle 293 (86 to 97)90 (82 to 95)
End of Treatment (Cycle 6)88 (80 to 94)84 (76 to 91)
Best Overall Response Rate98 (92 to 99)96 (89 to 98)
SecondaryComplete Response Rate

Complete Response Rate is defined as the percentage of participants with the best response of Complete Response (CR). Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. CR=Disappearance of all evidence of disease.

Time frame:
End of Cycle 2, End of Treatment (Cycle 6) [Median of 16 weeks on treatment]
Reported as:
Number · percentage of participants
Complete Response Rate
percentage of participantsRCHOPVc-RCHOP
End of Cycle 223 (16 to 33)16 (9 to 24)
End of Treatment (Cycle 6)45 (35 to 56)56 (45 to 65)
Best Complete Response Rate49 (39 to 59)56 (45 to 65)
SecondaryDuration of Response

Duration of response is defined as the time (in months) from the date of first documentation of confirmed complete response (CR) or partial response (PR) to the date of first documentation of progressive disease (PD), relapse from CR or death related to disease. For a participant who has not progressed and is not known to have died due to disease under study at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), duration of response is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using IWG-revised response criteria for malignant lymphoma. CR=Disappearance of all evidence of disease and PR=Regression of measurable disease and no new sites and PD= any new lesion or increase by \> 50% of previously involved sites from nadir.

Time frame:
Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm
Reported as:
Median · months
Duration of Response
monthsRCHOPVc-RCHOP
Duration of ResponseNA (NA to NA)NA (NA to NA)
SecondaryFluorodeoxyglucose Positron Emission Tomography (FDG-PET) Negative Rate

FDG-PET negative rate is defined as the percentage of participants FDG-PET negative at the given time-point.

Time frame:
End of Cycle 2 and End of Treatment (Cycle 6) [Median of 16 weeks on treatment]
Reported as:
Number · percentage of participants
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Negative Rate
percentage of participantsRCHOPVc-RCHOP
End of Cycle 242 (32 to 52)37 (27 to 47)
End of Treatment (Cycle 6)53 (43 to 64)59 (49 to 68)
SecondaryTime to Progression (TTP)

TTP is defined as the time from the date of randomization to the date of first documentation of progressive disease, relapse from CR, or death related to disease under study if participant did not have any documentation of disease progression prior to death caused by lymphoma or complications thereof. For a participant who has not progressed and is not known to have died due to disease under study at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), TTP is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. PD= any new lesion or increase by \> 50% of previously involved sites from nadir.

Time frame:
Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm
Reported as:
Median · months
Time to Progression (TTP)
monthsRCHOPVc-RCHOP
Time to Progression (TTP)NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants With Treatment Emergent Adverse Events (TEAEs) by Category

Percentage of participants in the following categories: • At least 1 TEAE • Drug-related, TEAEs • Grade 3 or higher TEAEs. Grade 3 are AEs of Severe Intensity • Grade 3 or higher drug-related, TEAEs • TEAEs resulting in study drug discontinuation • Serious TEAEs An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A Serious Adverse Event (SAE) is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Time frame:
First dose of study drug through 30 days after the last dose of study drug (Up to 26 Weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) by Category
percentage of participantsRCHOPVc-RCHOP
At Least 1 TEAE10099
Drug-related, TEAEs8895
Grade 3 or higher TEAEs7179
Grade 3 or Higher Drug-related, TEAEs5568
TEAEs Resulting in Study Drug Discontinuation46
Serious TEAEs3134
SecondaryPercentage of Participants With Chemistry and Hematology Laboratory Values Grade 3 or Higher

Percentage of participants who shifted from a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 0, 1, or 2 at Baseline to a Grade 3 or higher on study (worst post-baseline grade). Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe or medically significant but not immediately life-threatening, Grade 4=Life-threatening consequences and 5=Death related to AE.

Time frame:
Days 1, 4 and 10 of each cycle and end of treatment visit (Median of 16 weeks on treatment)
Reported as:
Number · percentage of participants
Percentage of Participants With Chemistry and Hematology Laboratory Values Grade 3 or Higher
percentage of participantsRCHOPVc-RCHOP
Lymphocytes7086
WBC Count6869
Neutrophils6570
Platelets1839
Hemoglobin1015
Hyperglycemia149
Hypokalemia1314
Hypophosphatemia710
Hyponatremia43
Alanine aminotransferase (ALT) increased21
Aspartate aminotransferase (AST) increased12

Adverse events

Collected over First dose of study drug through 30 days after the last dose of study drug (Up to 26 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RCHOP—31/100 (31%)100/100 (100%)
Vc-RCHOP—34/101 (33.7%)100/101 (99%)
Most frequent serious events
Showing 10 of 79
Most frequent serious events
EventRCHOPVc-RCHOP
Febrile neutropeniaBlood and lymphatic system disorders8/1007/101
DehydrationMetabolism and nutrition disorders2/1006/101
NeutropeniaBlood and lymphatic system disorders5/1001/101
PyrexiaGeneral disorders4/1004/101
SyncopeNervous system disorders0/1004/101
PneumoniaInfections and infestations3/1001/101
Herpes zosterInfections and infestations1/1003/101
Orthostatic hypotensionVascular disorders1/1003/101
PancytopeniaBlood and lymphatic system disorders2/1001/101
AnaemiaBlood and lymphatic system disorders2/1001/101
Most frequent other events
Showing 10 of 73
Most frequent other events
EventRCHOPVc-RCHOP
FatigueGeneral disorders70/10055/101
NauseaGastrointestinal disorders56/10051/101
AlopeciaSkin and subcutaneous tissue disorders51/10044/101
ConstipationGastrointestinal disorders45/10044/101
NeutropeniaBlood and lymphatic system disorders44/10038/101
ThrombocytopeniaBlood and lymphatic system disorders20/10039/101
AnaemiaBlood and lymphatic system disorders30/10037/101
Neuropathy peripheralNervous system disorders20/10032/101
InsomniaPsychiatric disorders26/10029/101
Decreased appetiteMetabolism and nutrition disorders27/10024/101

Baseline characteristics

Intent-to-treat (ITT) Population included all randomized participants who had at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)RCHOPVc-RCHOPTotal
Mean59.8 ± 14.6061.9 ± 13.8160.9 ± 14.21
Age, Customized
Age, Customized(participants)RCHOPVc-RCHOPTotal
≤ 65 years5855113
> 65 years424688
Gender
Gender(Participants)RCHOPVc-RCHOPTotal
Female435194
Male5750107
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RCHOPVc-RCHOPTotal
Hispanic or Latino61420
Not Hispanic or Latino9082172
Unknown or Not Reported459
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)RCHOPVc-RCHOPTotal
White7779156
Black or African American10919
Asian6511
Other459
Not Reported336
Region of Enrollment
Region of Enrollment(participants)RCHOPVc-RCHOPTotal
United States100101201
Height
Height(cm)RCHOPVc-RCHOPTotal
Mean171.1 ± 11.30170.3 ± 11.48170.7 ± 11.37
Weight
Weight(kg)RCHOPVc-RCHOPTotal
Mean85.19 ± 20.68482.86 ± 21.74584.02 ± 21.203

1 further baseline measures are reported on the registry.

08

Study locations

70 sites
  • Tower Cancer Research Foundation
    Beverly Hills, California 90211, United States
  • Fountain Valley Regional Hospital
    Fountain Valley, California 92708, United States
  • St. Jude Heritage Healthcare
    Fullerton, California 92835, United States
  • Moores Cancer Center- UCSD
    La Jolla, California 92093, United States
  • Antelope Valley Cancer Center
    Lancaster, California 93534, United States
  • Loma Linda University Cancer Center
    Loma Linda, California 92354, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Jonsson Comprehensive Cancer Center
    Los Angeles, California 90095, United States
  • TORI- Central Pharmacy
    Los Angeles, California, United States
  • TORI- Central Regulatory
    Los Angeles, California, United States
  • Oncology Care Medical Associates
    Montebello, California 90640, United States
  • Bay Area Cancer Research Group
    Pleasant Hill, California 94523, United States
  • Wilshire Oncology Medical Group
    Rancho Cucamonga, California 91730, United States
  • Sharp Healthcare
    San Diego, California 32123, United States
  • Central Coast Medical Oncology Corporation
    Santa Maria, California 93454, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33619, United States
  • Florida Cancer Specialists & Research Institute
    Gainsville, Florida 32605, United States
  • Alves/ Domenech Oncology-Hematology Clinic
    Hollywood, Florida 33019, United States
  • Florida Cancer Institute ATI
    New Port Richey, Florida 34655, United States
  • MD Anderson Cancer Center of Orlando
    Orlando, Florida 32806, United States
  • Coastal Oncology, PL
    Ormond Beach, Florida 32174, United States
  • Winship Cancer Institute at Emory University
    Atlanta, Georgia 30322, United States
  • Georgia Cancer Specialists
    Atlanta, Georgia 30341, United States
  • Dublin Hematology and Oncology
    Dublin, Georgia 31021, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Central Indiana Cancer Centers
    Fishers, Indiana 46227, United States
  • Cancer Care Center Inc. P.C.
    New Albany, Indiana 47150, United States
  • Iowa Blood and Cancer Care
    Cedar Rapids, Iowa 52401, United States
  • Iowa Oncology Research Association
    Des Moines, Iowa 50309, United States
  • Siouxland Hematology and Oncology Associates LLP
    Sioux City, Iowa 51101, United States
  • Kansas City Cancer Center, LLC
    Overland Park, Kansas 66210, United States
  • Sinai Hospital of Baltimore
    Baltimore, Maryland 21215, United States
  • St. Agnes Hospital of Baltimore
    Baltimore, Maryland 21229, United States
  • Holy Cross Hospital
    Silver Spring, Maryland 20910, United States
  • Lahey Clinic Medical Center
    Burlington, Massachusetts 01805, United States
  • Berkshie Hematology Oncology
    Pittsfield, Massachusetts 01201, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Mid Michigan Physicians
    Lansing, Michigan 48912, United States
  • Duluth Clinic
    Duluth, Minnesota 55805, United States
  • St. Luke's Hospital Cancer Care Center
    Duluth, Minnesota 55805, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • Saint Luke's Cancer Institute
    Kansas City, Missouri 64111, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Hematology/Oncology Associates of Northern New Jersey, P.A.
    Morristown, New Jersey 07962, United States
  • Hematology Oncology Associates of South Jersey
    Mount Holly, New Jersey 08060, United States
  • St. Luke's- Roosevelt Medical Center
    New York, New York 10019, United States
  • Cornell
    New York, New York, United States
  • Raleigh Hematology Oncology Associates P.C.
    Raleigh, North Carolina 27607, United States
  • Summa Health System
    Akron, Ohio 44304, United States
  • Oncology Hematology Care
    Cincinnati, Ohio 45267, United States
  • Kaiser Group Health
    Portland, Oregon 97227, United States
  • Hematology and Oncology Associates of NEPA
    Dunmore, Pennsylvania 18512, United States
  • UPMC Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Guthrie Clinic
    Sayre, Pennsylvania 18840, United States
  • Berks Hematology Oncology Associates
    W Reading, Pennsylvania 19611, United States
  • South Carolina Oncology Associates, PA
    Columbia, South Carolina 29201, United States
  • Chattanooga Oncology and Hematology Associates, PC
    Chattanooga, Tennessee 37404, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Texas Oncology Cancer Center
    Austin, Texas 78731, United States
  • US Oncology- Central Drug
    Fort Worth, Texas 76177, United States
  • US Oncology- Central Laboratory
    Fort Worth, Texas 76177, United States
  • Oncology Consultants P.A.
    Houston, Texas 77024, United States
  • Oncology Consultants
    Houston, Texas 77030, United States
  • US Oncology- Central Regulatory
    The Woodlands, Texas 77380, United States
  • Tyler Cancer Center
    Tyler, Texas 75702, United States
  • Texoma Cancer Center
    Wichita Falls, Texas 76310, United States
  • Virginia Cancer Institute
    Richmond, Virginia 23230, United States
  • Puget Sound Cancer Centers
    Edmonds, Washington 98026, United States
  • Northwest Cancer Specialists PC
    Vancover, Washington 98686, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2009
First posted
Jul 2, 2009
Start
Oct 2009
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Results first posted
Jan 11, 2017
Last update
Jan 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00931918
Responsible party
Sponsor
First posted
Jul 2, 2009
Start date
Oct 2009
Primary completion
Aug 2015
Completion
Aug 2015
Results posted
Jan 11, 2017
Last update
Jan 11, 2017

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bortezomib

Start the discussion